SEC Filing Summary: Bellevue Life Sciences Acquisition Corp.
Business Context and Reporting Period
This Form 8-K was filed on October 4, 2024, by Bellevue Life Sciences Acquisition Corp. (BLAC), a Special Purpose Acquisition Company (SPAC) incorporated in Delaware. The filing addresses a critical listing status event regarding the company's compliance with Nasdaq Capital Market requirements. The company's securities, including Units (BLACU), Common Stock (BLAC), Warrants (BLACW), and Rights (BLACR), are traded on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on regulatory compliance and listing status rather than financial performance.
Material Changes and Listing Status
- Initial Non-Compliance: On February 15, 2024, Nasdaq notified the company of failure to meet the minimum 300 public holders requirement (Listing Rule 5550(a)(3)).
- Compliance Plan: A plan to regain compliance was approved on April 17, 2024, granting an extension until August 13, 2024.
- Failure to Comply: On August 20, 2024, Nasdaq issued a second notice stating the company failed to regain compliance within the granted period.
- Hearing Outcome: A hearing was held on October 1, 2024. On October 4, 2024, the Hearings Panel granted the company's request for continued listing.
Outlook, Risks, and Contingencies
The continued listing is conditional. The company must demonstrate compliance with Listing Rule 5505 on or before February 17, 2025. During this exception period, the company is required to provide prompt notification of any significant events that may affect its compliance with Nasdaq requirements. Failure to meet the February 2025 deadline could result in delisting.
Key Facts for Investor Verification
- Verify the current number of public holders to assess the likelihood of meeting the February 17, 2025, compliance deadline.
- Monitor for any future Nasdaq notices or company announcements regarding significant events affecting listing status.
- Confirm the specific requirements of Listing Rule 5505 to understand the exact metrics needed for compliance.
- Note that this filing contains no financial performance data; investors should refer to recent 10-Q or 10-K filings for financial health.